Novo Nordisk’s semaglutide meets primary endpoint of reducing cardiovascular events at Phase 3
November 26, 2018Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide
Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met …
Mundipharma’s Neulasta biosimilar approved in EU
November 26, 2018Sales and Marketing Amgen, EU, Europe, Mundipharma, Neulasta, Pelmeg, pharma
Mundipharma has revealed that Pelmeg, its biosimilar version of Amgen’s Neulasta (pegfilgrastim), has been awarded marketing approval by the European …
Top Ten most popular articles on Pharmafile.com this week!
November 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kymriah, Mundipharma, UK, US, brexit, pharma, politics, top 10
The appointment of GSK veteran Arnaud Breabout to the position of Senior Vice President and CFO of Mundipharma took the …
Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype
November 23, 2018Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss
Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …
Immuno Biotech owner promoting unlicensed ‘cure’ for cancer, autism and HIV to be sentenced next week
November 23, 2018Medical Communications Cancer, David Noakes, GcMAF, HIV, UKIP, autism
The owner of Guernsey-based biotech Immuno Biotech Ltd, David Noakes, will be sentenced this week after admitting to a number …
New report finds link between social media and poor mental health among young people
November 23, 2018Medical Communications
Young people between the ages of 11 and 19, living with a mental disorder, were more likely to use social …
NHS hospitals paying 167% more for drugs since 2010/11
November 23, 2018Medical Communications Cost, NHS, UK, hospitals, pricing
Medicines are costing the NHS more than 50% more than a decade ago, while hospitals are paying more than twice …
Pfizer’s Daurismo becomes first of its kind to secure FDA approval in acute myeloid leukaemia
November 22, 2018Research and Development, Sales and Marketing AML, Daurismo, FDA, Pfizer, US, leukaemia
Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …
Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer
November 22, 2018Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma
MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …
GSK retain top spot on access to medicines list
November 22, 2018Business Services, Research and Development GSK, J&J, JJ, R&D, Sanofi, access, low and middle income countries, researh
The majority (63%) of research and development projects are being conducted by just five companies; GSK, Johnson & Johnson, Sanofi, …
Probiotics have no effect on children with gastroenteritis, study shows
November 22, 2018Research and Development children, flu, gastroenteritis, probiotics, research
Despite the claims of marketing campaigns and advertisements, probiotics have no effect on gastroenteritis on children, according to a new …
Uninsured patients elibible for no-cost replacement of medicines lost in California wildfires
November 22, 2018Manufacturing and Production, Sales and Marketing USA, california, insurance, prescription, wildfires
Uninsured citizens in California’s Butte, Los Angeles and Ventura counties will be eligible for a no-cost replacement of medicines lost …
FDA approves first ever therapy for ultra rare primary haemophagocytic lymphohistiocytosis
November 21, 2018Research and Development, Sales and Marketing FDA, Novimmune, pharma, sobi
The partnership of Sobi and Novimmune has revealed that their interferon gamma (IFNγ) blocking antibody Gamifant (emapalumab-lzsg) has received approval …
Mylan’s Morgantown plant receives FDA warning letter
November 21, 2018Research and Development Mylan, pharma
Generic drugmaker Mylan has received a warning letter from the FDA over concerns surrounding the firm’s manufacturing plant in West …
MHRA Chief to step down in 2019
November 21, 2018Medical Communications, Research and Development MHRA, UK, brexit, pharma
The Medicines and Healthcare products Regulatory Agency (MHRA), the regulator responsible for the efficacy and safety of medicines in the …
Pfizer ask Senator Cindy Hyde-Smith to refund campaign donation after ‘public hanging’ comments
November 21, 2018Research and Development Pfizer, cindy hyde smith, donations, politics, public hanging
American pharma giant Pfizer have asked Mississippi Republican Senator Cindy Hyde-Smith to return campaign donations after the candidate was filmed …
Brexit referendum led to rise in antidepressant prescriptions
November 21, 2018Research and Development
The result of the Brexit referendum led to an increase in prescriptions for antidepressants, according to a study conducted by …
First-ever all-oral drug for sleeping sickness recommended for approval by EMA committee
November 20, 2018Manufacturing and Production, Sales and Marketing CHMP, EMA, Europe, Sanofi, fexinidazole, pharma, sleeping sickness
Sanofi’s fexinidazole, the first all-oral therapy for the treatment of human African trypanosomiasis (HAT), or sleeping sickness, has secured a …
Opioid dependency therapy price hiked 600% since 2014, Senate investigators find
November 20, 2018Manufacturing and Production, Sales and Marketing Evzio, Kaleo, Senate, US, naloxone, opioid crisis, opioid epidemic, opioids, pharma
Senate investigators have found that Virginia-based drugmaker Kaleo hiked the price of its opioid dependency therapy Evzio (naloxone) by as …
Merck KGaA and Pfizer’s Bavencio falls short in ovarian cancer
November 20, 2018Manufacturing and Production, Research and Development Bavencio, Cancer, Merck MGaA, Pfizer, ovarian cancer, pharma
Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
